<DOC>
	<DOCNO>NCT02460887</DOCNO>
	<brief_summary>The purpose study verify induction gemcitabine cisplatin plus intensity-modulated radiotherapy ( IMRT ) non-inferior concurrent weekly cisplatin plus IMRT patient locoregionally advanced nasopharyngeal carcinoma ( NPC ) .</brief_summary>
	<brief_title>The Role Induction Gemcitabine Cisplatin Locoregionally Advanced Nasopharyngeal Carcinoma Era IMRT</brief_title>
	<detailed_description>Patients non-keratinizing NPC T1-4N2-3或T3-4N0-1M0 ( UICC/AJCC 7th edition ) randomly assign receive induction chemotherapy CCRT alone . Patients experimental group receive gemcitabine ( 1000 mg/m² d1,8 ) cisplatin ( 80mg/m² d1 ) every 3 week 2 cycle intensity-modulated radiotherapy ( IMRT ) . Patients control group receive IMRT concurrently weekly cisplatin 40 mg/m² 7cycles . IMRT give 2.0-2.33 Gy per fraction five daily fraction per week 6-7 week total dose 66 Gy great primary tumor . Our primary endpoint failure-free survival ( FFS ) . Secondary end point include overall survival ( OS ) , locoregional failure-free survival ( LR-FFS ) , distant failure-free survival ( D-FFS ) rate toxic effect . All efficacy analysis conduct intention-to-treat population , safety population include patient receive randomly assign treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients newly histologically confirm nonkeratinizing nasopharyngeal carcinoma ( include WHO II III ) . Tumor stag T14N23或T34N01M0 ( accord 7th AJCC edition ) . Satisfactory performance status : Karnofsky scale ( KPS ) ≥ 70 . Adequate marrow : leucocyte count ≥ 4000/μL , hemoglobin ≥ 90g/L platelet count ≥ 100000/μL . Adequate liver function : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) &lt; 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) ≤ 2.5×ULN , bilirubin ≤1.5×ULN . Adequate renal function : creatinine clearance ≥ 60 ml/min . Patients must inform investigational nature study give write informed consent . WHO Type keratinize squamous cell carcinoma basaloid squamous cell carcinoma . Treatment palliative intent . Prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer . Pregnancy lactation ( consider pregnancy test woman childbearing age emphasize effective contraception treatment period ) . History previous RT ( except nonmelanomatous skin cancer outside intend RT treatment volume ) . Prior chemotherapy surgery ( except diagnostic ) primary tumor node . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>nasopharyngeal carcinoma</keyword>
	<keyword>induction chemotherapy</keyword>
</DOC>